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R. A. J. van Deelen5, Frank Jan de Jong6, Esther M. Opmeer7,8, André Aleman7, Craig W. Ritchie9,
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Abstract
Background: The cognitive-functional composite (CFC) was designed to improve the measurement of clinically
relevant changes in predementia and early dementia stages. We have previously demonstrated its good test-retest
reliability and feasibility of use. The current study aimed to evaluate several quality aspects of the CFC, including
construct validity, clinical relevance, and suitability for the target population.
Methods: Baseline data of the Capturing Changes in Cognition study was used: an international, prospective
cohort study including participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI),
Alzheimer’s disease (AD) dementia, and dementia with Lewy bodies (DLB). The CFC comprises seven existing
cognitive tests focusing on memory and executive functions (EF) and the informant-based Amsterdam Instrumental
Activities of Daily Living Questionnaire (A-IADL-Q). Construct validity and clinical relevance were assessed by (1)
confirmatory factor analyses (CFA) using all CFC subtests and (2) linear regression analyses relating the CFC score
(independent) to reference measures of disease severity (dependent), correcting for age, sex, and education. To
assess the suitability for the target population, we compared score distributions of the CFC to those of traditional
tests (Alzheimer’s Disease Assessment Scale–Cognitive subscale, Alzheimer’s Disease Cooperative Study–Activities of
Daily Living scale, and Clinical Dementia Rating scale).
Results: A total of 184 participants were included (age 71.8 ± 8.4; 42% female; n = 14 SCD, n = 80 MCI, n = 78 AD,
and n = 12 DLB). CFA showed that the hypothesized three-factor model (memory, EF, and IADL) had adequate fit
(CFI = .931, RMSEA = .091, SRMR = .06). Moreover, worse CFC performance was associated with more cognitive
decline as reported by the informant (β = .61, p < .001), poorer quality of life (β = .51, p < .001), higher caregiver
burden (β = − .51, p < .001), more apathy (β = − .36, p < .001), and less cortical volume (β = .34, p = .02). Whilst correlations
between the CFC and traditional measures were moderate to strong (ranging from − .65 to .83, all p < .001), histograms
showed floor and ceiling effects for the traditional tests as compared to the CFC.
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Conclusions: Our findings illustrate that the CFC has good construct validity, captures clinically relevant aspects of disease
severity, and shows no range restrictions in scoring. It therefore provides a more useful outcome measure than traditional
tests to evaluate cognition and function in MCI and mild AD.
Keywords: Alzheimer’s disease, Cognition, Composite, Daily function, Dementia, Construct validation, Instrumental
activities of daily living, Mild cognitive impairment, Outcome measures
Background
Alzheimer’s disease (AD) is the leading cause of demen-
tia worldwide and has been the target of clinical trials
and intervention studies for many years [1]. In the past
decade, the research field has shifted towards earlier
clinical stages of dementia and to predementia stages
such as mild cognitive impairment (MCI) [2]. Remark-
ably, the selection of cognitive and functional outcome
measures to evaluate treatment effects has not been
adapted to the shift in treatment target populations.
Measures originally designed for mild to severe demen-
tia, such as the Alzheimer’s Disease Assessment Scale–
Cognitive subscale (ADAS-Cog [3]), are still widely used
as primary endpoints in MCI and early AD dementia tri-
als. Several studies have shown that those older, trad-
itional measures are insensitive to change over time in
MCI and mild dementia [4, 5], as they focus on cognitive
domains and everyday activities that are unaffected in
those disease stages [5–7]. This limits their clinical rele-
vance in the predementia window and leads to range re-
strictions in scoring (i.e., floor and ceiling effects) [4, 8].
Hence, researchers and regulatory agencies have
expressed the urgent need for a sensitive measure that is
capable of detecting clinically relevant changes at early
clinical stages of AD [9–13]. The same holds for
dementia with Lewy bodies (DLB), the second most
common cause of dementia, of which both pathology
and clinical manifestations show considerable overlap
with AD [14, 15].
The Capturing Changes in Cognition (Catch-Cog) pro-
ject was initiated to fulfill the need for a sensitive, clinic-
ally relevant outcome measure for use in MCI and mild
dementia. We designed a novel cognitive-functional
composite (CFC) measure in our expert working group,
basing our selections on previously published work and
input from MCI and dementia patients and caregivers
[16]. The resulting CFC consists of a short cognitive test
battery focusing on memory and executive functioning
(EF) [17], as these are the cognitive domains that have
been shown to decline in predementia and early stages
of dementia [13]. The rationale of specific cognitive tests
included in this battery has been described in more de-
tail elsewhere [16]. Briefly, the selection was based on
empirical evidence on their sensitivity to change, as
reflected by the absence of floor and ceiling effects in
MCI and mild AD [17]. To amplify its clinical relevance, we
augmented the cognitive test battery with a previously vali-
dated everyday functioning measure: the Amsterdam Instru-
mental Activities of Daily Living Questionnaire (A-IADL-Q)
[18]. The A-IADL-Q assesses the problems in cognitively
complex everyday activities such as cooking, managing fi-
nances, and using technological devices [19, 20]. In item re-
sponse theory analyses, these activities were found to be the
activities most sensitive to cognitive decline [21]. The
A-IADL-Q was previously demonstrated to be sensitive to
the decline in dementia, as well as able to capture difficulties
in instrumental activities of daily living (IADL) functioning
in MCI and subjective cognitive decline (SCD) [21, 22].
Combining these cognitive and functional measures
into the CFC summarizes cognitive and everyday per-
formance and may thereby provide a single clinically
relevant score. Both the Food and Drug Association
(FDA) and the European Medical Agency (EMA) en-
courage the use of such composite endpoints to evaluate
novel drug therapies and interventions [11, 12]. These
agencies also stipulate that composite measures should
be (1) carefully designed, (2) validated in an independent
prospective cohort study, and (3) “bear some relevance
to existing tools for which historical experience exists”
[12]. In the Catch-Cog study, we have sought to meet
these criteria by performing an extensive construct valid-
ation of the CFC. In a previous report, we demonstrated
that the CFC exhibits high test-retest reliability and good
feasibility of use [23], which are pivotal prerequisites for
a reliable and valid outcome measure [24]. Having dem-
onstrated this, we embarked on a longitudinal construct
validation in an independent prospective cohort across
the clinical spectrum from SCD to mild dementia. The
main aim of this study is to validate the CFC in MCI
and mild AD dementia stages, but we will also explore
whether the CFC could be of use in individuals with
SCD and DLB.
In the current study, we performed a psychometric
evaluation of the CFC using baseline data of the
Catch-Cog study. We aimed to evaluate several quality
aspects of the CFC, including the construct validity, clin-
ical relevance, and suitability for the target population.
Therefore, we investigated the CFC’s factor structure
and compared the CFC score with reference measures of
disease severity such as informant reports and global
Jutten et al. Alzheimer's Research & Therapy           (2019) 11:45 Page 2 of 13
cortical atrophy [16]. We also examined CFC score dis-
tributions in direct comparison to currently used tests,
including the ADAS-Cog [3], the Clinical Dementia Rat-
ing scale Sum of Boxes (CDR-SB) [25], the Alzheimer’s
Disease Cooperative Study–Activities of Daily Living
scale (ADCS-ADL) [26], and the Alzheimer’s Disease
Composite Score (ADCOMS) procedure [27].
Methods
Study design and participants
In this cross-sectional study, we employed baseline data
from the Catch-Cog study, which is an international, multi-
center, prospective cohort study. Participants (N = 184) were
recruited via the (1) Alzheimer Center Amsterdam,
Amsterdam UMC, location VU University Medical Center,
The Netherlands (n = 102); (2) Alzheimer Center Erasmus
Medical Center (EMC, n= 14), Rotterdam, The Netherlands;
(3) University Medical Center Groningen (UMCG, n= 39),
The Netherlands; and (4) the Centre for Dementia Preven-
tion, Edinburgh, Scotland (n= 29). We recruited participants
who met the research criteria for SCD [28], the clinical cri-
teria for MCI due to AD [2], probable AD dementia [29], or
DLB dementia [15]. Other inclusion criteria were (1)
Mini-Mental State Examination (MMSE) score ≥ 18, (2) age
≥ 50, and (3) availability of a study partner who was able and
willing to participate. Exclusion criteria were (1) presence of
any other neurological disorder, (2) presence of a major psy-
chiatric disorder such as severe personality disorder or de-
pression (Geriatric Depression Scale score ≥ 6 [30]), (3)
current abuse of alcohol and/or drugs, and (4) simultan-
eously participating in a clinical trial.
Before inclusion, participants had undergone a stand-
ard diagnostic work-up in their study center, including
at least medical history, neurological examination, and
cognitive assessment. Structural brain imaging was avail-
able for a subset of the study cohort. Diagnoses were
performed during a multidisciplinary consensus meeting,
containing at least a neurologist or psychiatrist and with
neuropsychology input. In the UMCG, SCD, and MCI,
participants were also recruited via advertisements in
local newspapers. After responding to this advertise-
ment, eligible participants were screened by a neuro-
psychologist and neurologist to investigate whether they
met the criteria for SCD or MCI [28].
The Medical-Ethical Committee of the VU University
Medical Center approved the study for all Dutch centers.
The South East Scotland Research Ethics Committee ap-
proved the study for the Scottish site. All participants and
study partners provided written and oral informed consent.
The cognitive-functional composite
Cognitive component
The cognitive test battery of the CFC included the three
ADAS-Cog memory subscales Word Recognition, Word
Recall and Orientation [3]; the Controlled Oral Word
Association Test (COWAT); category fluency test (CFT);
Digit Span Backward (DSB) and Digit Symbol Substitu-
tion Test (DSST) [31]. During the word recognition test,
the participant is required to learn a list of 12 words and
identify these words when mixed among 12 other dis-
tracter words (one point for each incorrect response,
score range 0–12). During word recall, the participant is
given three trials to learn a list of ten high-imagery
nouns (total score entails the average number of words
not recalled across the three trials, score range 0–10).
The orientation subtest includes eight questions regard-
ing the participant’s orientation to person, place, and
time (one point for each incorrect response, score range
0–8). The COWAT assesses the participant’s phonemic
fluency skills using the letters D-A-T in The Netherlands
or F-A-S in English and a total time of 60 s per letter
(one point for each correct non-repeated word). The
CFT examines the participant’s semantic fluency by re-
quiring them to generate as many exemplars of the cat-
egory animals within 60 s (one point for each correct
unique animal). The DSB requires the participant to re-
produce sequences of digits of increasing length in the
reversed order (score range 0–12). The DSST is a timed
EF test during which participants have to substitute as
many digits by unique geometric symbols within 90 s
(one point for each correct substituted symbol).
Functional component
The functional component consisted of the short version
of the A-IADL-Q [21]. The A-IADL-Q is a computer-
ized, informant-based questionnaire covering a broad
range of complex IADL [19]. The short version consists
of 30 items covering household, administration, work,
computer use, leisure time, appliances, and transport ac-
tivities. For each item, difficulty in performance is rated
on a 5-point Likert scale (ranging from “no difficulty in
performing this task” to “no longer able to perform this
task”). Scoring is based on item response theory, a para-
digm linking item responses to an underlying latent trait
[32]. This results in a latent trait score (z-score), reflect-
ing one’s level of IADL functioning, with higher scores
indicating better IADL functioning [21].
CFC scoring
To create CFC scores, the directionality of the three
ADAS-Cog subtest scores were reversed, so that higher
scores reflected better performance. Subsequently, all
cognitive subtest scores were transformed into z-scores
with total group mean and standard deviation (SD) as
reference values. The cognitive composite was computed
as a weighted z-score of all seven cognitive subtests,
whereas the functional component score was the
A-IADL-Q score. The overall CFC composite score was
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computed as a weighted z-score of the cognitive com-
posite and A-IADL-Q, with higher scores indicating bet-
ter performance.
Reference measures
Traditional tests of cognition and function
Traditional tests to compare the CFC with included the
MMSE, ADAS-Cog-13, ADCS-ADL, and CDR-SB. The
MMSE is a global cognitive screening test, with a total
score ranging from 0 to 30 and higher scores reflecting
better performance [33]. The ADAS-Cog-13 yields a
measure of cognitive performance by combining ratings
of 13 subtests (e.g., word lists recognition and recall,
constructional praxis, object and finger naming). Total
scores range from 0 to 85, with higher scores indicating
more severe impairment [3]. The ADCS-ADL assesses
the functional abilities affected in mild-to-moderate AD.
For 23 different basic and instrumental activities, the
levels of performance and independency during the past
4 weeks were rated by the study partner. Total scores
range from 0 (non-performance or need for extensive
help) to 78 (independent performance) [26]. The CDR
has been developed for the staging of dementia severity.
The participant’s cognitive and functional performance
is rated in 6 areas: memory, orientation, judgment and
problem solving, community affairs, home and hobbies,
and personal care. Each area is rated as 0 (healthy), 0.5
(questionable dementia), 1 (mild dementia), 2 (moderate
dementia), or 3 (severe dementia). Adding the rating of
all boxes results in a total CDR-SB score ranging from 0 to
18, with higher scores reflecting severe dementia [25, 34].
The ADCOMS is a recently designed, statistically derived
composite scoring procedure, consisting of two MMSE items
(“orientation to time” and “copy design”), 4 ADAS-Cog sub-
tests (delayed word recall, orientation, word recognition, and
word recall) and all 6 CDR-SB subscores. All items are differ-
entially weighted yielding a score ranging from 0 to 1.27 with
higher scores implying greater impairment [27].
Reference measures of disease severity
Informant reports of disease severity included the Cog-
nitive Function Instrument study partner ver-
sion (CFI-SP) [35], Quality of Life in Alzheimer’s Disease
(QoL-AD) [36], the short version of Zarit Burden Inven-
tory (ZBI-12) [37], and the Apathy Evaluation Scale
(AES) [38]. The CFI-SP includes 14 items on a decline
in day-to-day cognitive and functional abilities compared
to 1 year ago. Response options include “yes” (0), “no”
(1), or “maybe” (0.5), with total scores ranging from 0 to
14. The QoL-AD consists of 13 items, rated on a 4-point
scale. Total scores range from 13 to 52, with higher
scores reflecting better quality of life. The ZBI is one of
the most commonly used instruments for assessing the
aspects of caregiver burden [37]. Each item was rated on
a 5-point scale, with total scores ranging from 0 to 60
and higher scores suggesting greater caregiver burden.
The AES consists of 18 statements about the partici-
pant’s thoughts, feelings, and activity, which are rated on
a 4-point scale. Total scores range from 0 to 72, with
higher scores indicating more severe apathy.
Magnetic resonance (MR) images were acquired lo-
cally at each center in 3 T scanners. A minimum accept-
able protocol was approved and then optimized at each
site due to scanner differences (see Additional file 1).
The images were checked for quality by an experienced
rater. Volumetric measurements were processed on 3D
T1-weighted (3DT1) images with Statistical Parametric
Mapping 12 (SPM12) software (Wellcome Trust Centre
for Neuroimaging, University College London, UK) run-
ning in MATLAB 2011a (MathWorks Inc., Natick, MA,
USA). Prior to processing, the origin in each scan was
manually set to the anterior commissure. Scans were
segmented into gray matter (GM), white matter (WM),
and cerebrospinal fluid (CSF). Total GM (i.e., the sum of
all GM voxels) and total intracranial volume (TIV) (i.e.,
the sum of GM, WM, and CSF volumes) were derived
from the segmented images in native space (units in
liter). Cortical volume was defined as the total GM vol-
ume normalized for head size, divided by TIV.
Procedures
Study visits took place at the hospital or the participant’s
home, depending on the participant’s preference. A
trained rater assessed the cognitive tests according to
standardized instructions, starting with the MMSE and
followed by the cognitive part of the CFC (word recogni-
tion, orientation, CFT, COWAT, DSST, DSB, word re-
call) and the remaining ADAS-Cog-13 tests. In the
meantime, the study partner completed the A-IADL-Q,
ZBI, and QoL-AD independently on an iPad. Subse-
quently, the participant completed the QoL-AD on the
iPad with assistance from the rater. Finally, the rater
completed the ADCS-ADL and CDR interview with the
study partner. The total duration of a complete assess-
ment was approximately 90 min. A shortened protocol
was used in the SCD and DLB participants, as it was not
our purpose to compare the CFC to the traditional tests
that were not designed to assess the progression in these
groups. Therefore, SCD and DLB participants only
underwent the MMSE and cognitive battery of the CFC
whilst their study partner completed the A-IADL-Q.
MRI procedures
MR scans acquired less than 6months prior to the study
visit were available for a subset of the study cohort. These
included at least 3D T1- and T2-weighted imaging (T2)
and 3D fluid-attenuated inversion recovery (FLAIR). Par-
ticipants without a recent MRI scan available but who
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agreed to undergo a structural MRI scan were also
scanned at 3 T with the same structural sequences which
took about 30min.
Statistical analyses
Statistical analyses were performed using SPSS version 22.0
(IBM Corp., Armonk, NY) and R Studio (R Core Team,
2018). Statistical significance level was set at p value < .05,
unless otherwise indicated. Demographic and clinical differ-
ences between the groups were investigated using chi-square
tests, one-way analyses of variance (ANOVA) followed by
Hochberg’s post hoc tests, and independent t tests for mea-
sures only available for the MCI and AD group.
Construct validity and clinical relevance
We performed confirmatory factor analyses (CFA) in-
cluding all CFC subtests to investigate the CFC’s under-
lying factor structure. We evaluated a single-factor,
two-factor (memory and EF), and three-factor (memory,
EF, and IADL) model. In the two-factor model, the
memory factor included the word recognition, orienta-
tion, and word recall tests and the EF factor included
the CFT, COWAT, DSST, DSB, and A-IADL-Q. The
three-factor model had a similar memory and EF factor,
except that the A-IADL-Q was excluded from the EF
factor and included a separate factor. We compared
these models using chi-square tests and by evaluating
their Comparative Fit Index (CFI), root mean squares of
error approximation (RMSEA), and standardized root
mean square residual (SRMR) indices, with CFI ≥ .90,
RMSEA < .08, and SRMR < .08 considered as adequate
fit [39]. We hypothesized that the three-factor model
would fit, based on preparatory work on the cognitive
component showing two underlying factors [40], and
A-IADL-Q reflecting one underlying factor [19]. As a
sensitivity analysis, all aforementioned CFA model evalu-
ations were repeated in a restricted sample of MCI and
mild AD participants, as this was the primary target
population of the CFC.
Next, we investigated the differences in CFC scores
across diagnostic groups using ANOVA followed by
Hochberg’s post hoc tests, to examine whether scores
would decrease from SCD to dementia. We assessed the
association between the CFC variables and reference
measures of disease severity, by performing linear re-
gression analyses for each reference measure (CFI-SP,
QoL-AD, ZBI-12, and AES, as dependent) and CFC
score, age, sex and education as independents. To evalu-
ate the added clinical value of the A-IADL-Q, we also
investigated a second model including the cognitive
component score and A-IADL-Q score as separate inde-
pendents. The association between CFC score and gray
matter volume was assessed with a linear regression ana-
lysis correcting for age, sex, years of education, and
scanner type. We computed Pearson’s correlation coeffi-
cients to investigate the relation between CFC scores
and traditional cognitive and functional measures.
Quality for the target population
As the CFC was initially designed for MCI and mild AD
dementia, the comparison analyses with traditional mea-
sures and ADCOMS were performed using the MCI and
AD groups only. Using this sample, we compared histo-
grams of score distributions of the CFC, traditional tests,
and ADCOMS to inspect range restrictions in scoring. To
allow for appropriate comparisons between the CFC com-
ponents and traditional tests, the histograms for the
ADAS-Cog, ADCS-ADL, and CDR-SB score distributions
were based on the standardized scores. Additionally, we
reported original score ranges and distribution parameters
(percentiles, skewness, and kurtosis) for all tests.
Results
Descriptive characteristics
The total sample (N= 184) had a mean age of 71.8 ± 8.4
years, 42% were female, and mean years of education was
13.6 ± 3.8. The majority had a diagnosis of MCI (n= 80) or
AD dementia (n= 78). Table 1 presents the demographic
and clinical characteristics separately for each diagnostic
group. Groups differed in terms of age (F= 2.99, p= .033),
but there were no significant differences regarding sex and
education. MMSE scores were lower for dementia (AD, 24.0
± 3.3; DLB, 24.8 ± 3.1) compared to MCI (26.7 ± 2.3) and
SCD (29.3 ± 1.2). The AD group also performed worse on
the ADAS-Cog (mean difference 6.3 points, p < .001),
ADCS-ADL (mean difference 3.8 points, p= .01) and
CDR-SB (mean difference 2.4 points, p < .001) when com-
pared to the MCI group. Study partners of AD participants
reported worse CFI-SP scores (mean difference 2
points, p < .001), lower quality of life scores (mean
difference 2.2 points, p = .026), higher caregiver bur-
den (mean difference 3.7 points, p = .004), and higher
apathy levels (mean difference 3.4 points, p = .039)
compared to study partners of MCI participants.
Construct validity and clinical relevance
CFA showed that the hypothesized three-factor model
including memory, EF, and IADL had an adequate fit
(CFI = .931, RMSEA = .091 (90% CI = .058–.124 and
SRMR = .06), although the RMSEA index did not reach
the predefined cutoff (< .08). The three-factor model
(Fig. 1) described the data better than the single- or
two-factor models (Table 2). Similar results were found
after repeating the analyses in a restricted sample of
MCI and mild AD participants (CFI = .918, RMSEA = .09
(90% CI = .053–.122 and SRMR = .06).
As expected, overall CFC scores decreased concomi-
tantly to progression across the spectrum from SCD
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(.89 ± .57) to MCI (.29 ± .51) and to AD or DLB demen-
tia (AD, − .39 ± .61; DLB, − .52 ± .75), with significant dif-
ferences between all groups except the two dementia
groups (AD and DLB). A similar pattern was found for
the cognitive composite score. A-IADL-Q scores were
significantly lower for AD as compared to SCD and
MCI, as well as for DLB compared to MCI and SCD
(Table 1). Figure 2 visualizes the decreased scores across
the diagnostic groups, with the cognitive composite di-
vided into a memory and EF score according to the CFA
results. It also shows that the CFC score is similar for
the two dementia groups and that in AD, this score is
driven by the memory factor rather than the EF factor,
whereas the opposite is observed in DLB.
Lower CFC scores were associated with worse cogni-
tive functioning as reported by the informant (corrected
β = .61, p < .001), quality of life (corrected β = .51, p < .001),
caregiver burden (corrected β = − .51, p < .001), and apathy
level (corrected β = − .36, p < .001). Regression models in-
cluding the cognitive composite and A-IADL-Q as separate
scores demonstrated the added clinical value of the
A-IADL-Q (Table 3). We found moderate-to-strong
associations between the cognitive composite and
ADAS-Cog (r=− .83; 95% CI = − .87 to − .77), the
A-IADL-Q and ADCS-ADL (r= .65; 95% CI = .54–.73), and
CFC score and CDR-SB (r=− .69; 95% CI =− .77 to − .56).
Brain MR images were available for 70 participants (n = 7
SCD, n = 27 MCI, and n = 36AD). Linear regression ana-
lyses showed a significant association between normalized
GM volume and CFC score (corrected β = .34, p = .01,
Fig. 3), indicating that worse performance on the CFC was
related to less cortical volume independently of age, sex,
education, and scanner type.
Quality for the target population
Histograms including the total MCI and AD sample
(n = 158) showed expected floor and ceiling effects in
scoring for all the traditional measures (Fig. 4). Range
restrictions were especially apparent for the ADAS-
Cog and ADCS-ADL (Table 4). For example, for the
ADCS-ADL, 35% of the participant scores were at the
maximum end of the scale (between 70 and 78). By
comparison, all CFC components showed normal
distributions without range restrictions in scoring.
Figure 5 displays a direct comparison between the
ADCOMS and CFC score distributions, separately for
the MCI and mild AD dementia group. Despite
strong correlations between the ADCOMS and CFC
scores (r = − .76; 95% CI = − .82 to − .68), it can be
seen that the ADCOMS is more influenced by ceiling
effects in scoring, particularly in the MCI subgroup.
Table 1 Descriptive characteristics and test scores separately for each diagnostic group
SCD (n = 14) MCI (n = 80) AD (n = 78) DLB (n = 12) p value Post hoc between group comparisons*
Descriptives
Age 68.1 (6.6) 73.6 (8.0) 71.3 (9.1) 68.3 (6.1) .033 Non-significant
Female (%) 8 (57.1%) 29 (36.3%) 39 (50%) 2 (16.7%) .060 N.A.
Education 15.2 (4.8) 13.7 (3.6) 13.2 (4.0) 13.6 (3.3) .36 N.A.
MMSE 29.3 (1.2) 26.7 (2.3) 24.0 (3.3) 24.4 (2.9) < .001 SCD > MCI > AD; SCD >DLB
CFC components
Cognitive composite .88 (.50) .19 (.50) − .31 (.61) − .35 (.71) < .001 SCD > MCI > AD, SCD > DLB, MCI > DLB
A-IADL-Q .91 (.79) .39 (.73) − .48 (.84) − .65 (.90) < .001 SCD > AD; MCI < AD; SCD > DLB; MCI > DLB
CFC score .89 (.57) .29 (.51) − .39 (.61) − .51 (.75) < .001 SCD > MCI > AD; SCD > DLB; MCI > DLB
Reference measures
CFI-SP N.A. 6.9 (3.2) 4.9 (2.8) N.A. < .001 N.A.
QoL-AD N.A. 33.8 (5.3) 31.6 (5.2) N.A. .026 N.A.
ZBI-12 N.A. 10.7 (7.7) 14.4 (7.9) N.A. .004 N.A.
AES N.A. 39.9 (10.5) 43.3 (10.0) N.A. .053 N.A.
Traditional tests
ADAS-Cog N.A. 22.2 (6.8) 28.5 (7.6) N.A. < .001 N.A.
ADCS-ADL N.A. 67.5 (7.8) 63.7 (8.8) N.A. .010 N.A.
CDR-SB N.A. 2.7 (1.9) 5.1 (2.2) N.A. < .001 N.A.
Abbreviations: ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, ADCS-ADL Alzheimer’s Disease Cooperation Study–Activity of Daily Living, AES
Apathy Evaluation Scale, A-IADL-Q Amsterdam IADL Questionnaire, CDR-SB Clinical Dementia Rating Sum of Boxes, CFC cognitive-functional composite, CFI-SP
Cognitive Function Instrument study partner version, MMSE Mini-Mental State Examination, QoL Quality of life, ZBI Zarit Burden Inventory
*Based on Hochberg’s post hoc tests
Jutten et al. Alzheimer's Research & Therapy           (2019) 11:45 Page 6 of 13
Discussion
We performed a psychometric evaluation of the novel
CFC. Factor analyses confirmed the underlying structure
of the CFC, reflecting the domain memory, EF, and
IADL. The associations that we found between the CFC
score and reference measures of disease severity further
supported the construct validity and clinical relevance of
the CFC. We also demonstrated that the CFC scores
yielded fewer range restrictions in scoring as compared
to traditional tests of cognition and function, indicating
a better quality for the target population.
Construct validity, clinical relevance, and suitability for
the target population are important quality aspects for
clinical outcome measures [41]. Construct validity refers
to whether an instrument measures what it intends to
measure [24]. As a first step to assess this, we performed
a CFA which confirmed that our novel combination of
tests can be described by a memory, EF, and IADL com-
ponent. Interestingly, we observed that the two cogni-
tion factors contributed differentially to the overall CFC
score as seen in AD versus DLB, with the AD group
scoring worse on the memory component compared to
Fig. 1 Path diagrams showing the three-factor structure of the CFC, including the covariance between domains and variables
Table 2 Fit statistics for confirmatory factor analysis models




Model 1: single factor 62.952 20 < .001 .891 .108 [.079–.139] .070 N.A. N.A.
Model 2: MEM + EF 52.543 19 < .001 .915 .098 [.067–.130] .064 ChiSq(1) = 10.409, p = .001 N.A.
Model 3A: MEM + EF + IADL 45.269 18 < .001 .931 .091 [.058–.124] .060 Chisq(2) = 17.683, p < .001 Chisq(1) = 15.873, p < .001
Model 1: Single factor based on all eight CFC subtests
Model 2: MEM =Word Recognition + Orientation +Word Recall, EF = Controlled Word Association Test + Category Fluency + Digit Symbol Substitution + Digit Span
Backward + Amsterdam IADL Questionnaire
Model 3: MEM =Word Recognition + Orientation +Word Recall, EF = Controlled Word Association Test + Category Fluency + Digit Symbol Substitution + Digit Span
Backward, IADL = Amsterdam IADL Questionnaire
Abbreviations: CFI Comparative Fit Index, EF executive functioning, IADL instrumental activities of daily living; MEM memory, RMSEA Root mean squares of error
approximation, SRMR Standardized root mean square residual
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the EF component and the DLB group vice versa. Not-
ably, this is in line with the clinical pictures of both dis-
eases with memory problems as the most prominent
symptoms of early AD as opposed to more predominant
EF problems in early DLB [14]. These results further
confirm that the CFC score is an adequate reflection of
the dimensionality of the construct to be measured.
Another aspect of construct validity is testing whether
scores on an instrument are associated with scores on in-
struments that measure a similar construct [24]. We
found moderate-to-strong associations with the traditional
measures of cognition and function, which supports the
construct validity of the CFC. It should, however, be noted
that cognitive composite included three ADAS-Cog mea-
sures, which probably accounts for the strong association
we found between these measures. We also demonstrated
that the CFC is associated with other clinically relevant
measures of disease severity, such as cognitive decline as
reported by the informant, quality of life, caregiver bur-
den, and apathy. Additionally, the association between
CFC score and GM volume, which has shown to be a
good biomarker of neurodegeneration in AD [42, 43],
Fig. 2 Box plots displaying scores on the CFC subcomponents (memory, EF, and IADL factor) and the overall CFC score, separately for each
diagnostic group
Table 3 Beta coefficients obtained from linear regression analyses relating CFC components to reference measures of disease severity
CFI-SP QoL-AD ZBI-12 AES
Beta 95% CI p value Beta 95% CI p value Beta 95% CI p value Beta 95% CI p value
Model 1
CFC score .61 .48 .74 < .001 .51 .37 .65 < .001 − .51 − .65 − .37 < .001 − .36 − .51 − .20 < .001
Age .14 .02 .27 .028 − .06 − .20 .08 .388 − .08 − .21 .06 .280 − .01 − .16 .14 .913
Sex .21 .08 .34 .002 .10 − .04 .24 .171 − .19 − .33 − .05 .009 − .19 − .34 − .04 .014
Education − .04 − .17 .09 .578 − .13 − .27 .02 .087 .20 .06 .34 .006 .05 − .10 .21 .507
Model 2
Cognitive composite − .09 − .24 .06 .226 − .10 − .26 .07 .254 − .02 − .19 .15 .815 − .01 − .20 .18 .915
A-IADL-Q .72 .58 .86 < .001 .62 .46 .77 < .001 − .52 − .68 − .36 < .001 − .37 − .55 − .19 < .001
Age .11 − .01 .23 .066 − .09 − .22 .04 .182 − .06 − .19 .08 .409 .01 − .14 .16 .945
Sex .18 .06 .30 .004 .07 − .06 .20 .305 − .17 − .31 − .03 .017 − .18 − .33 − .03 .021
Education .04 − .09 .16 .552 − .06 − .20 .08 .405 .16 .02 .30 .030 .02 − .14 .18 .791
Abbreviations: AES Apathy Evaluation Scale, A-IADL-Q Amsterdam IADL Questionnaire, CFC cognitive-functional composite, CFI-SP Cognitive Function
Instrument study partner version, QoL Quality of life, ZBI Zarit Burden Inventory
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Fig. 3 Scatterplot displaying the correlation between the CFC score and gray matter volume (corrected for total intracranial volume)
Fig. 4 Score distributions of the CFC components and traditional tests in a combined sample of MCI and mild AD subjects (n = 158). Scores are
standardized using the total sample mean and standard deviation as reference values
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illustrates that the CFC assesses a construct that is
related to the underlying disease process. Taken to-
gether, these associations suggest that several clinic-
ally relevant aspects of the disease and its severity are
captured by the CFC.
Quality for the target population was evaluated by
inspecting range restrictions in scoring in our MCI and
early dementia sample. This population largely corre-
sponds with “stage 3 patients” as described in the re-
cently proposed NIA-AA clinical staging scheme and
Table 4 Score ranges, percentiles, and distribution parameters for the traditional test scores and CFC scores
Score range Percentiles Distribution
Original Current sample 5 10 25 50 75 90 95 Skewness Kurtosis
ADAS-Cog 0–80 6–47 14 16 19 26 30 35 40 .236 .217
ADCS-ADL 0–78 39–78 47 55 60 68 73 75 77 − .902 .477
CDR-SB 0–18 0–12 .5 .7 2.0 3.5 5.5 7.0 8.7 .596 .142
ADCOMS 0–1.47 .05–1.21 .10 .15 .28 .43 .61 .86 .99 .620 − .042
A-IADL-Q N.A. − 2.01–1.95 − 1.71 − 1.32 − .64 .00 .63 1.04 1.42 − .091 − .457
Cognitive Composite N.A. − 1.44–1.33 − 1.13 − .88 − .52 − 0.04 .40 .81 .96 − .046 − .445
CFC N.A. − 1.51–1.37 − 1.14 − .87 − .42 − 0.04 .38 .78 .88 − .136 − .440
Abbreviations: ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, ADCOMS Alzheimer’s Disease Composite Score, ADCS-ADL Alzheimer’s Disease
Cooperation Study–Activity of Daily Living, CDR-SB Clinical Dementia Rating Sum of Boxes, CFC cognitive-functional composite
Fig. 5 Score distributions of the CFC and ADCOMS, separately for MCI (n = 80) and mild AD dementia (n = 78)
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aligned FDA guidance [11, 44]. We found that both the
traditional tests and the recently designed ADCOMS
showed ceiling effects in scoring in this stage, indicating
that these participants showed a high level of function-
ing. These ceiling effects hamper the measurement of
changes and especially the measurement of potential im-
provement due to treatment. In contrast, the score dis-
tributions of the CFC component were normally
distributed, showing potential to indicate both decline
and improvement with respect to baseline measure-
ments. Therefore, these cross-sectional results support
that the CFC is a promising measure with which to as-
sess changes over time without exhibiting the limitations
of traditionally used tests.
Several other endeavors have been undertaken to de-
sign and validate composite measures that are more ap-
propriate to assess changes earlier clinical stages of AD.
These composites range from purely statistically driven
[27, 45] to more theoretically based such as the preclin-
ical Alzheimer’s cognitive composite (PACC) [46] and
the Alzheimer prevention initiative cognitive composite
(APCC) [47]. The PACC and APCC focus on preclinical
stages of AD and do not include a measure of daily func-
tion. However, measuring everyday functioning is highly
relevant in the MCI and dementia stages, as evolving
IADL problems are an important clinical hallmark in the
transitional stage from MCI to dementia and predict a
future decline in dementia [7]. The ADCOMS procedure
includes a functional measure (CDR-SB), and the fact
that previously changes were detected in a clinical trial
[27] supports the idea that adding a functional measure
advances a cognitive outcome measure. However, the
ADCOMS selection has been largely driven by statistical
considerations rather than its content, and therefore, its
clinical relevance is as yet uncertain. It is our view that the
CFC can contribute to the existing initiatives to improve
cognitive measurement in the MCI and mild dementia
stages, as its composition has been based on both theoret-
ical constructs (i.e., the combination of cognition and
IADL measure) and empirical research [17, 22].
There are some limitations to consider. First, not all
MCI and AD participants had AD biomarkers available,
and therefore, it is unknown whether they had AD path-
ology. However, in these circumstances, we relied on an
extensive clinical assessment and excluded participants
with other conditions that could have caused or contrib-
uted to the cognitive or functional symptoms. Second,
some heterogeneity in our sample may have been caused
by minor differences in the recruitment strategies
employed across the centers as well as from including
SCD and DLB participants. Consequently, our sample
may not perfectly mirror the composition of an ideal
clinical trial sample. It should also be noted that the
SCD and DLB samples were relatively small and that the
CFC investigations in these groups were of explorative
nature. This limits the interpretation of the CFC results
in those groups. Additionally, the sample size of partici-
pants with an MRI scan available was relatively small, as
this was not required for participation in our study.
Therefore, we should be careful with interpreting
these findings, particularly in the SCD group. A
further limitation is that we have only investigated a
single weighting method to create the CFC score,
whereas it is likely that the optimal scoring method
involves different weights for the different compo-
nents. For example, our data showed that the memory
component seems to be relatively easy compared to
the EF component, which might be something that
we need to account for when tracking the changes
over time, in particular for the MCI group. Lastly, the
fact that the CFC in its current composition focuses
less on other domains than episodic memory and EF
may limit its usefulness for measuring progression at
more severe stages of dementia.
Strengths of this study include our construct validity
approach, which is a unique aspect of the Catch-Cog
study. Given the lack of a gold standard for “disease se-
verity,” we used different reference measures of disease
severity to compare the CFC with, which led to conver-
ging evidence for the clinical relevance of the CFC. Add-
itionally, we were able to perform a direct head-to-head
comparison between the CFC and traditional tests,
which, to our knowledge, has never been done in previ-
ous studies. The advantage of this is to reveal both the
strengths and weaknesses of different clinical measure-
ments. Furthermore, our investigation of the CFC in an
independent, prospective cohort is an essential aspect of
this study. Although the CFC consists of tests that have
been validated as part of other test batteries and across
several study cohorts, it cannot be assumed that all mea-
sures perform similarly in a novel composition. For ex-
ample, tests may perform differently when assessed in a
different test order. An independent validation of a novel
composite measure such as the CFC measure is thus
needed to enhance future implementation. We are cur-
rently assessing the CFC longitudinally in our Catch-
Cog prospective study cohort, and we will investigate its
sensitivity to change after 3, 6, and 12 months and com-
pare its sensitivity with that of the traditional tests. This
longitudinal data will also enable us to explore whether
different weights for the subtests can improve the
sensitivity to change over time, as well as whether
different weights are useful when tracking a change in
different diagnostic groups. For example, putting
more weight on the cognitive parts and activities of
daily living that decline relatively late in the disease
course may enhance the use of the CFC to track pro-
gression in later disease stages.
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Conclusions
We demonstrated that the CFC has good construct val-
idity and captures clinically relevant aspects of disease
progression. We also showed its improved suitability for
the target population as compared to traditional tests, as
reflected by fewer range restrictions in scoring. These
findings illustrate that the CFC has good potential to be a
sensitive, clinically meaningful outcome measure. It is
therefore better indicated for use to evaluate cognition and
function as compared to traditional tests, as in line with the
recent FDA recommendations. Ultimately, the CFC can
yield a more accurate and useful measurement of clinically
relevant changes, which will aid the monitoring of disease
progression and evaluation of novel treatments.
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